2025-07-23 - Analysis Report
Okay, here's a report analyzing Recursion Pharmaceuticals Inc. (RXRX), based on the data you provided.

## Recursion Pharmaceuticals Inc. (RXRX) Analysis

**Ticker:** RXRX
**Company:** Recursion Pharmaceuticals Inc.
**Description:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging artificial intelligence to discover, develop, and commercialize novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -39.49%
*   **VOO Cumulative Return:** 36.18%
*   **Spread (RXRX - VOO):** -75.67%

**Spread Analysis:**
*   **Max Spread:** 35.8
*   **Min Spread:** -88.1
*   **Current Spread:** -77.0
*   **Relative Spread:** 9.0

**Interpretation:** RXRX has significantly underperformed the S&P 500. The relative spread of 9.0 suggests that RXRX is near the lower end of its historical performance relative to the index. It is at the bottom 9% relative to VOO.

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2021-2023  | 5.0%   | 73.6%  | -1.0%  | -0.1  | 4.3    |
| 2022-2024  | 0.0%   | 73.6%  | -25.0% | 0.1  | 2.9    |
| 2023-2025  | 12.0%  | 73.6%  | -37.0% | 0.1  | 2.8    |

**Analysis:**
*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows a volatile performance.
*   **MDD:** High Maximum Drawdown (MDD) indicates significant risk.
*   **Alpha:** Consistently negative Alpha suggests underperformance compared to the benchmark.
*   **Beta:** Low Beta indicates low correlation with the market.

### 2. Recent Price Action

*   **Current Price:** $6.54
*   **Previous Close:** $6.40
*   **Change:** 2.19%
*   **5-Day Moving Average:** 5.938
*   **20-Day Moving Average:** 5.4412
*   **60-Day Moving Average:** 5.0107

**Analysis:** The price is above all three moving averages (5-day, 20-day, and 60-day), which is generally a bullish signal. The recent price increase of 2.19% suggests positive momentum.

### 3. Technical Indicators & Outlook

*   **Market Risk Indicator (MRI):** 0.3359 (Low Risk)
*   **RSI:** 72.18 (Overbought)
*   **PPO:** 1.92
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) (Cash Ratio: 0% on 2025-07-08)
*   **Delta_Previous_Relative_Divergence (20-day):** 7.4 (+) (Short-term increase)
*   **Expected Return:** -257.1% (Long-term, relative to S&P 500)

**Analysis:**
*   The MRI indicates low market risk.
*   The RSI suggests the stock is currently overbought, potentially indicating a pullback.
*   The positive change in relative divergence indicates a short-term upward trend.
*   The significantly negative expected return suggests a pessimistic long-term outlook compared to the S&P 500.
*   **Recent Market Volatility**: The 2.19% increase from the previous close suggests that the recent news might be causing a rapid price increase.

### 4. Recent News & Significant Events

*   **[2025-07-22]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-19]:** Analyst discussions on recent performance and outlook.
*   **[2025-07-23]:** Notable stock volatility due to recent news, earnings reports, or executive actions.
*   **[2025-07-20]:** Market experts highlight both risks and opportunities.

**Analysis:** The news suggests that RXRX is currently experiencing significant volatility and is subject to market speculation. Investors should closely monitor these events.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-05-05 | -0.50 | 0.01 B$    |
| 2024-11-06 | -0.34 | 0.03 B$    |
| 2024-08-08 | -0.40 | 0.01 B$    |
| 2024-05-09 | -0.39 | 0.01 B$    |
| 2025-05-05 | -0.39 | 0.01 B$    |

**Analysis:** Earnings per share (EPS) is consistently negative, indicating a lack of profitability. Revenue generation is relatively low.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |
| 2024-03-31 | $0.01B  | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE    |
|------------|---------|--------|
| 2025-03-31 | $0.93B  | -21.68% |
| 2024-12-31 | $1.03B  | -17.29% |
| 2024-09-30 | $0.52B  | -18.27% |
| 2024-06-30 | $0.58B  | -16.69% |
| 2024-03-31 | $0.40B  | -22.78% |

**Analysis:**
*   **Revenue and Profitability:** Revenue is inconsistent, and profit margins are generally negative, particularly in recent quarters.
*   **Capital and Profitability:** Return on Equity (ROE) is negative, suggesting poor profitability relative to equity. Equity fluctuates, indicating changes in the company's financial structure.

### 7. Overall Summary

Recursion Pharmaceuticals (RXRX) has significantly underperformed the S&P 500, with negative alpha and high maximum drawdown. While there has been a recent price increase, the RSI suggests the stock is overbought.  The company faces challenges in profitability, as evidenced by negative EPS, fluctuating revenue, and negative profit margins. News sources indicate recent volatility and events affecting the stock. Long-term projections estimate significant underperformance relative to the S&P 500. The recent jump in price might be tied to news events, but caution is advised due to the negative earnings and long-term outlook.

**Disclaimer:** This analysis is based on the data provided and should not be considered financial advice. Consult with a financial professional before making any investment decisions.
